文献速递泌尿生殖PETMR

镓68前列腺特异性膜抗原PET/MRI与多参数MRI检测临床显著性前列腺癌的诊断效能比较

Diagnostic Performance of 68Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer.
PubMed 文献 · Radiology · 2021-08-31

99名PSA 2.5-20 ng/mL的男性前瞻性接受镓68-PSMA PET/MRI(含多参数MRI序列),78例行活检,25例(32%)检出临床显著性前列腺癌(ISUP分级组≥2)。PSMA PET/MRI特异性高于多参数MRI(76% vs 49%,P < .001),敏感度相似(88% vs 92%,P > .99);PI-RADS 3病变中特异性也更高(86% vs 59%,P = .002)。

要点

  • PSMA PET/MRI对临床显著性前列腺癌的特异性高于多参数MRI(76% vs 49%,P < .001)。
  • PI-RADS 3病变中PSMA PET/MRI特异性为86%,高于多参数MRI的59%(P = .002)。
  • 决策曲线分析显示,靶向PSMA摄取的活检仅在PI-RADS 3病变中增加多参数MRI的净获益。

核心结论

  • 镓68-PSMA PET/MRI较之多参数MRI提高了对临床显著性前列腺癌的特异性,尤其在PI-RADS 3病变中。

研究设计与样本

  • 前瞻性研究,纳入2019年6月至2020年3月间PSA 2.5-20 ng/mL的99名男性,行镓68-PSMA PET/MRI(含多参数MRI序列),由两名放射科医师独立采用PI-RADS v2.1评估;参考标准为ISUP分级组≥2的临床显著性前列腺癌;78例行活检,25例(32%)确诊。

诊断标准与关键数值

  • 临床显著性前列腺癌定义为ISUP分级组≥2;PSMA PET/MRI vs 多参数MRI:特异性76% [95% CI: 62, 86] vs 49% [95% CI: 35, 63](P < .001),敏感度88% [95% CI: 69, 98] vs 92% [95% CI: 74, 99](P > .99);PI-RADS 3病变特异性86% [95% CI: 73, 95] vs 59% [95% CI: 43, 74](P = .002)。

临床应用与阅片要点

  • 对于PI-RADS 3病变,结合PSMA摄取情况可提高特异性,可能有助于减少不必要活检;PI-RADS 4和5病变中,无论PSMA摄取如何,靶向活检净获益相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Gallium 68 (68Ga) prostate-specific membrane antigen (PSMA) PET/MRI may improve detection of clinically significant prostate cancer (CSPC). Purpose To compare the sensitivity and specificity of 68Ga-PSMA PET/MRI with multiparametric MRI for detecting CSPC. Materials and Methods Men with prostate specific antigen levels of 2.5-20 ng/mL prospectively underwent 68Ga-PSMA PET/MRI, including multiparametric MRI sequences, between June 2019 and March 2020. Imaging was evaluated independently by two radiologists by using the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1. Sensitivity and specificity for CSPC (International Society of Urological Pathology grade group ≥ 2) were compared for 68Ga-PSMA PET/MRI and multiparametric MRI by using the McNemar test. Decision curve analysis compared the net benefit of each imaging strategy. Results Ninety-nine men (median age, 67 years; interquartile range, 62-71 years) were included; 79% (78 of 99) underwent biopsy. CSPC was detected in 32% (25 of 78). For CSPC, specificity was higher for 68Ga-PSMA PET/MRI than multiparametric MRI (76% [95% CI: 62, 86] vs 49% [95% CI: 35, 63], respectively; P < .001). Sensitivity was similar (88% [95% CI: 69, 98] vs 92% [95% CI: 74, 99], respectively; P > .99). For PI-RADS 3 lesions, specificity was also higher for 68Ga-PSMA PET/MRI than for multiparametric MRI: 86% (95% CI: 73, 95) versus 59% (95% CI: 43, 74), respectively (P = .002). Decision curve analysis showed that biopsies targeted to PSMA uptake increased the net benefit of multiparametric MRI only among PI-RADS 3 lesions. The net benefit of targeted biopsy for a PI-RADS 3 lesion with PSMA uptake was higher across all threshold probabilities over 8%. The net benefit of targeted biopsy was similar for PI-RADS 4 and 5 lesions, regardless of PSMA uptake. Conclusions Gallium 68 prostate-specific membrane antigen PET/MRI improved specificity for clinically significant prostate cancer compared with multiparametric MRI, particularly in Prostate Imaging Reporting and Data System grade 3 lesions. © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Williams and Estes in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Margel D, Bernstine H, Groshar D, et al. Diagnostic Performance of 68Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer. Radiology. 2021. PMID: 34463555. doi:10.1148/radiol.2021204093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。